Nextsource Materials Inc (NSRCF)

[StoogeNo4]

Volume = 1,250 shares so far today. How miserable is that?

Stellar was 33 cents one year ago today. It's ~$1.77 today. And the announcement below is why. Stellar has had breakthroughs. ENZR has had discoveries. Why can't ENZR present at investor conferences? Why can't we be financing at $1?...or at least 35 cents or more like everybody else in our field?

Maser: don't tell me to ask Brent! The answer will be nonsensical back-stepping and theories about a supposed master plan.

STELLAR BIOTECHNOLOGIES, INC. TO PRESENT AT TWO INVESTOR CONFERENCES IN JANUARY

PORT HUENEME, CA, (January 6, 2014) -- Stellar Biotechnologies, Inc. ("Stellar" or “the Company”) (OTCQB: SBOTF) (TSX-V: KLH),) announced today that the Company will present at two upcoming investor conferences in January: the Biotech Showcase 2014 in San Francisco and the Noble Financial Capital Markets Tenth Annual Equity Conference in South Florida.

Frank Oakes, Stellar’s President and CEO will present at both conferences, providing an overview of the Company, its programs and milestones, and 2014 corporate objectives. Members of Stellar’s executive team will be available for meetings at both events.

Biotech Showcase™ 2014
Date and Time: January 14, 2014, 4:00 PM PST
Venue Location: Parc 55 Wyndham San Francisco, CA
Conference Website: http://www.ebdgroup.com/bts/index.php

Noble Financial Capital Markets Tenth Annual Equity Conference
Date and Time: January 21, 2014, 8:00 AM EST
Venue Location: Club Med Sandpiper Bay, Sandpiper Bay, Florida
Conference Website: http://www.nobleresearch.com/TEN/2014.htm

Presentation schedules and details will be posted on Stellar’s website at http://stellarbiotechnologies.com/investors/profile_presentations/ .

About Stellar Biotechnologies, Inc.

Stellar Biotechnologies, Inc. (TSX-V: KLH) (US OTCQB: SBOTF) is the world leader in sustainable manufacture of Keyhole Limpet Hemocyanin (KLH), an important immune-stimulating protein used in wide-ranging therapeutic and diagnostic markets. KLH is both an active pharmaceutical ingredient (API) in many new immunotherapies (targeting cancer, infectious diseases, and immune disorders) as well as a finished product for measuring immune status. Stellar Biotechnologies is unique in its proprietary methods, facilities, and KLH technology. We are committed to meeting the growing demand for commercial-scale supplies of GMP grade KLH, ensuring environmentally sound KLH production, and developing KLH-based active immunotherapies.

To receive regular updates, enter email at http://stellarbiotechnologies.com/contact/

Visit www.StellarBiotech.com and the KLH knowledge base www.KLHSite.com.

Company Contacts:

Frank Oakes
President and CEO
Phone [phone]
[e-mail]

Mark A. McPartland
Vice President of Corporate Development and Communications
Phone: [phone]
[e-mail]
www.stellarbiotech.com